Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, announced an agreement with Tokyo-based SCRUM Inc. to expand its presence in Japan’s research community. This collaboration will provide researchers in academia and industry with full access to Parse’s innovative single cell sequencing solutions. “Biotech, pharma, and academic researchers throughout Asia are rapidly adopting Parse’s Evercode single cell sequencing solutions because of their scalability and simplicity,” said Alex Rosenberg, PhD, CEO and co-founder of Parse Biosciences. “By partnering with SCRUM, we are ensuring that researchers in Japan can easily leverage Parse’s advanced single cell sequencing technology to accelerate their discoveries.” Through this agreement, SCRUM will distribute Parse’s comprehensive portfolio of single cell solutions throughout Japan, including: Evercode™ Cell and Nuclei Fixation Evercode™ Whole Transcriptome Evercode™ TCR Evercode™…
Otsuka Shokai Co. Ltd. announced that it will start offering "Tayoreru EDR Advisory Service for…
Telexistence Inc. has joined the AI Robot Association as a board member and has begun…
In GovTech news this week… 🔹 Plus and TIER IV Partner to Advance Autonomy 2.0…
Amazon Web Services (AWS) has launched its new quantum computing chip, "Ocelot." This move puts…
Veeva Systems announced that Boehringer Ingelheim has launched its own drug discovery platform, "One Medicine Platform," through the successful implementation…
Guardant Health, Inc., a leading precision oncology company, and ConcertAI, a leading oncology real-world evidence data and AI SaaS technology…
Primo Biotechnology ("Primo") has announced a strategic collaboration with SHINE Technologies ("Shine"), a global leader in nuclear medicine manufacturing. The…
CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, announced it…
Daiichi Sankyo Company, Ltd announced that it will pay Glycotope $132.5 million to acquire intellectual property rights of the anti-tumor-associated…
Sign in to your account